Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

Leukemia

Volumn 22, Issue 12, 2008, Pages 2288-2291

  Pelz Ackermann, O ^a   Cross, M ^a   Pfeifer, H ^b   Deininger, M ^c   Wang, S Y ^a   Al Ali, H K ^a   Niederwieser, D ^a   Lange, T ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 57849103456     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.180     Document Type: Letter

References (9)

1. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy. Leukemia 2002; 16: 2190-2196.
2. Gruber FXE, Lamaek T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005; 19: 2159-2165.
3. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with cle novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727-734.
4. Willis SG, Lange T, Demehri S, Otto S, Crossmann L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
5. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: 1-13.
6. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276-283.
7. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem 2004; 50: 1205-1213.
8. O'Hare C, Eide CA, Deininger MWN. BCR-ABL kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia. Blood 2007; 110: 2242-2249.
9. Preuner S, Denk D, Frommlet F, Nesslboeck M, Lion T. Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia 2008; 22 1956-1961.